Evidence map›Paper›PMID 37609254›Full record

ArticlebioRxiv : the preprint server for biology2023

The AKT2/SIRT5/TFEB pathway as a potential therapeutic target in atrophic AMD.

Sayan Ghosh, Ruchi Sharma, Sridhar Bammidi, Victoria Koontz, Mihir Nemani, Meysam Yazdankhah, Katarzyna M Kedziora, Callen T Wallace, Cheng Yu-Wei, Jonathan Franks and 16 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 6 institutions in 4 countries.

Sayan Ghosh
Ruchi Sharma
Sridhar Bammidi
Victoria Koontz
Mihir Nemani
Meysam Yazdankhah
Katarzyna M Kedziora
Callen T Wallace
Cheng Yu-Wei
Jonathan Franks
Devika Bose
Dhivyaa Rajasundaram
Stacey Hose
José-Alain Sahel
Rosa Puertollano
Toren Finkel
J Samuel Zigler
Yuri Sergeev
Simon C Watkins
Eric S Goetzman
Miguel Flores-Bellver
Kai Kaarniranta
Akrit Sodhi
Kapil Bharti
James T Handa
Debasish Sinha
University of Pittsburgh · USNational Institutes of Health · USJohns Hopkins University · USCentre National de la Recherche Scientifique · FRUniversity of Colorado Anschutz Medical Campus · USUniversity of Eastern Finland · FI

Funding

Regulation of Peroxisomal Metabolism by Lysine AcylationR01DK090242 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GOETZMAN, ERIC S · 2011 to 2024
$5.4M
Targeting lysosome/RPE heterogeneity in AMD pathobiology as a novel therapyR01EY031594 · NEI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HANDA, JAMES T, SINHA, DEBASISH · 2021 to 2024
$2.4M
Optimizing medium-chain lipids for the treatment of long-chain fatty acid oxidation disordersR01HD103602 · NICHD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GOETZMAN, ERIC S · 2021 to 2025
$1.7M
NEI NIH HHS R01 EY031594NICHD NIH HHS R01 HD103602NIDDK NIH HHS R01 DK090242
6 · The paper itself

Abstract

Age-related macular degeneration (AMD), the leading cause of geriatric blindness, is a multi-factorial disease with retinal-pigmented epithelial (RPE) cell dysfunction as a central pathogenic driver. With RPE degeneration, lysosomal function is a core process that is disrupted. Transcription factors EB/E3 (TFEB/E3) tightly control lysosomal function; their disruption can cause aging disorders, such as AMD. Here, we show that induced pluripotent stem cells (iPSC)-derived RPE cells with the complement factor H variant [

Identifiers

PMID37609254
PMCPMC10441325
OpenAlexW4385704056

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.